SUBSCRIBE

Breaking News on Contract Research, Manufacturing & Clinical Trials

Exclusive interview

Once a friend now an enemy: Over zealous EU regulators could hamper the CMO market, says analyst

By Natalie Morrison , 25-Apr-2012
Last updated on 25-Apr-2012 at 14:14 GMT

Once a friend now an enemy: Over zealous EU regulators could hamper the CMO market, says analyst
Once a friend now an enemy: Over zealous EU regulators could hamper the CMO market, says analyst
Loading...

The European CMO industry could be blocked by over complex layers of regulation, says Frost & Sullivan analyst Aiswariya Chidambaram.

In part II of our pod series based on Chidambaram’s report ‘European Pharmaceutical and Biotech Contract Manufacturing Markets’, she predicted European contract manufacturing organisations (CMOs) could see a revenue boost from $10bn in 2011, to $20.75bn in 2018.

However, although stringent regulations in the region are an attraction for pharma firms looking to trust a firm with their outsourced work, she says the soaring costs of it could soon drag down the market’s progress.

She said: "The emerging markets like India and China are growing at robust rates compared to developing markets. These markets are becoming more technically well-equipped and become more and more WHO (World Health Organisation) compliant.

“With all these processes in place most the pharma companies are trying to establish their facilities in the emerging markets.”

Still with well established quality control processes, Chidambaram feels there is still a place for European CMOs, and that the market should focus on what it does best – complicated products .

“When we talk of manufacturing of highly regulated products or complicated products like biopharmaceuticals, I still say companies prefer to outsource to the developed markets like the US and indeed, Europe," she added.

Subscribe to our FREE newsletter

Get FREE access to authoritative breaking news, videos, podcasts, webinars and white papers. SUBSCRIBE

Related products

A bitter pill to swallow: young people dislike tablets more than old

A bitter pill to swallow: young people dislike tablets more than old

Thomas Hein

Director, Sales & Business Development, Hermes

Kemwell CEO says environmental efforts are worth the cost

Kemwell CEO says environmental efforts are worth the cost

Kemwell CEO Agneta Bergvall says drugmakers' efforts to make pharmaceutical manufacturing green are worth...

Catalent launches softgel products at CPhI: one vegetarian, one anti-abuse

Catalent launches softgel products at CPhI: one vegetarian, one anti-abuse

Will Downie

Senior VP Global Vusiness Development & Marketing, Catalent

AlpVision's iPhone Tech Offers Authentication in War on Counterfeits

AlpVision's iPhone Tech Offers Authentication in War on Counterfeits

Quincy Mattingly

Regional Manager, AlpVision

Cobra Biologics talks recent fill finish acquisition and future growth plans

Cobra Biologics talks recent fill finish acquisition and future growth plans

Philip Ridley-smith

Business Development & Marketing Manager, Cobra Biologics

Catalent says sharing with industry will not dull competetive edge

Catalent says sharing with industry will not dull competetive edge

Kurt Nielsen and Cornell Stamoran

Various, Catalent

Bend Research hunting new partnerships to boost bioavailability offering

Bend Research hunting new partnerships to boost bioavailability offering

David Lyon and Karen Coppens

Various, Bend Research and Dow

Changes to EU clinical trial laws will mean fairer playing field, says Clinipace

Changes to EU clinical trial laws will mean fairer playing field, says Clinipace

Andrea Schiefer

VP of European clinical operations and executive director of pharmacovigilance,...

Consolidation prevalent in industry, says third largest CMO

Consolidation prevalent in industry, says third largest CMO

Brad Carlson

VP Marketing 7 Sales, Aenova

Catalent commits to ADCs by upping its stake in Redwood

Catalent commits to ADCs by upping its stake in Redwood

Aileen Ruff

Global Strategic Marketing Director, Biologics and Sterile Technologies at Catalent...

Kemwell Talks Expansion and Approvals in India and the US

Kemwell Talks Expansion and Approvals in India and the US

Christian Ahlmark

Director of Corporate Development , Kemwell Biopharma

AMRI Exec Discusses 'New Bar' in FDA Enforcement

Following the completion of remediation efforts to deal with an FDA warning letter, Chris...

Happy holidays from William Reed Business Media!

Happy holidays from William Reed Business Media!

The working year is almost done, time to pause from ‘the business’ and embrace...

Aesica says academic partnerships are key for CMOs

Aesica says academic partnerships are key for CMOs

Alan Raymond

Sales & Marketing Director, Aesica Pharmaceuticals

Wockhardt targets CMO space for diversification

Wockhardt targets CMO space for diversification

Tom Salus

Associate Vice President, Business Development - Contract Services, Wockhardt

Kemwell and Boehringer set to finish biologics plant in India

Kemwell and Boehringer set to finish biologics plant in India

Christian Ahlmark

Director of corporate development , Kemwell